Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 10/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310748 | 1.00 | HPGDS (0.47) | HPGDSCNR2MAPK1PAK1GRIN2B | |
| SCHEMBL8271768 | 0.90 | PAK1 (0.49) | HPGDSCNR2PAK1GRIN2BLMNA | |
| SCHEMBL8271758 | 0.90 | PAK1 (0.49) | HPGDSCNR2PAK1GRIN2BLMNA | |
| SCHEMBL14349470 | 0.90 | PAK1 (0.49) | HPGDSCNR2PAK1GRIN2BMKNK1 | |
| SCHEMBL14349389 | 0.89 | CASP3 (0.50) | HPGDSPAK1 | |
| SCHEMBL14349442 | 0.89 | MAPK1 (0.45) | HPGDSCNR2MAPK1PAK1MKNK1 | |
| SCHEMBL14349391 | 0.88 | PAK1 (0.48) | HPGDSMAPK1PAK1LMNA | |
| SCHEMBL14349390 | 0.88 | GRIN2B (0.52) | HPGDSCNR2PAK1GRIN2BLMNA | |
| SCHEMBL8271771 | 0.88 | HPGDS (0.43) | HPGDSCNR2PAK1GRIN2B | |
| SCHEMBL8271761 | 0.88 | CNR2 (0.47) | HPGDSCNR2PAK1GRIN2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| WO-2006017409-A2 | 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | GRIN2B, GRIN2A, GRIN1 | HPGDS 1733/4885CNR2 270/4885MAPK1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.